SciELO - Scientific Electronic Library Online

 
vol.56 issue3ANALYSIS OF LACTOSE INTOLERANCE IN STUDENTS WITH SUGGESTIVE SYMPTOMS OF IRRITABLE BOWEL SYNDROMEBIOLOGICAL THERAPY PENETRATION FOR INFLAMMATORY BOWEL DISEASE IN LATIN AMERICA: CURRENT STATUS AND FUTURE CHALLENGES author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

Share


Arquivos de Gastroenterologia

Print version ISSN 0004-2803On-line version ISSN 1678-4219

Abstract

PERIN, Ramir Luan et al. VEDOLIZUMAB IN THE MANAGEMENT OF INFLAMMATORY BOWEL DISEASES: A BRAZILIAN OBSERVATIONAL MULTICENTRIC STUDY. Arq. Gastroenterol. [online]. 2019, vol.56, n.3, pp.312-317.  Epub Sep 30, 2019. ISSN 1678-4219.  https://doi.org/10.1590/s0004-2803.201900000-58.

BACKGROUND:

There is scarce data regarding efficacy and safety of vedolizumab in inflammatory bowel diseases in Latin America.

OBJECTIVE:

To describe the first observational real-world experience with vedolizumab in Latin American inflammatory bowel diseases patients.

METHODS:

Retrospective observational multicentric study of patients with Crohn’s disease (CD) and ulcerative colitis (UC) who used vedolizumab at any phase of their treatment. Clinical remission and response (according to Harvey-Bradshaw index for CD and Mayo score for UC), mucosal healing, need for surgery and adverse events were evaluated.

RESULTS:

A total of 90 patients were included (52 with CD and 38 with UC), the majority with previous exposure to anti-TNF agents (88.46% in CD and 76.31% in UC). In CD (as observed analysis) remission rates at weeks 12, 26 and 52 were 42.89% (21/49), 61.9% (26/42) and 46.15% (12/26), respectively. In UC, remission rates at weeks 12, 26 and 52 were 28.94% (11/38), 36.66% (11/30) and 41.17% (7/17). Mucosal healing rates were 36.11% in CD and 43.4% in UC. During the study period, 7/52 CD patients underwent major abdominal surgery and 4/38 UC patients needed colectomy.

CONCLUSION:

Vedolizumab was effective in induction and maintenance of clinical response and remission in CD and UC, with no new safety signs.

Keywords : Crohn disease; Ulcerative colitis; Inflammatory bowel diseases; Integrins; Monoclonal antibodies.

        · abstract in Portuguese     · text in English     · English ( pdf )